Over the past decade, several novel immunotherapies have transformed the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukaemia. In the pivotal TOWER trial, blinatumomab—a ...

The subcutaneous formulation can be administered by patients, caregivers, or healthcare professionals and is available as a vial or prefilled syringe. "This marks another milestone in our partnership ...

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme ...

Company News Published 06/20/2025, 01:22 PM 0 Argenx receives EU approval for VYVGART subcutaneous injection HALO 0.30% ...

April 27, 2021. Clair-Jones AS et al. Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. Rheumatology and Therapy. December 2020.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the Committee for Medicinal Products for Human Use (CHMP) of the ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European ...

This article discusses the differences and similarities between nivolumab subcutaneous injections and IV infusions for RCC to help people make the most suitable decisions for their treatment.